WO2000027363B1 - Aerosols comprising nanoparticle drugs - Google Patents
Aerosols comprising nanoparticle drugsInfo
- Publication number
- WO2000027363B1 WO2000027363B1 PCT/US1999/026799 US9926799W WO0027363B1 WO 2000027363 B1 WO2000027363 B1 WO 2000027363B1 US 9926799 W US9926799 W US 9926799W WO 0027363 B1 WO0027363 B1 WO 0027363B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- aerosol
- less
- nanoparticulate
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002350074A CA2350074C (en) | 1998-11-12 | 1999-11-12 | Aerosols comprising nanoparticle drugs |
JP2000580594A JP4758548B2 (en) | 1998-11-12 | 1999-11-12 | Aerosol comprising ultrafine drug |
AU13469/00A AU1346900A (en) | 1998-11-12 | 1999-11-12 | Aerosols comprising nanoparticle drugs |
EP99956981A EP1128814B1 (en) | 1998-11-12 | 1999-11-12 | Aerosols comprising nanoparticle drugs |
DE69943112T DE69943112D1 (en) | 1998-11-12 | 1999-11-12 | AEROSOLS CONTAINING PHARMACEUTICAL NANOPARTICLES |
AT99956981T ATE493971T1 (en) | 1998-11-12 | 1999-11-12 | AEROSOLS CONTAINING MEDICINAL NANOPARTICLES |
DK99956981.7T DK1128814T3 (en) | 1998-11-12 | 1999-11-12 | Aerosols comprising nanoparticulate drugs |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/190,138 | 1998-11-12 | ||
US09/190,138 US7521068B2 (en) | 1998-11-12 | 1998-11-12 | Dry powder aerosols of nanoparticulate drugs |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2000027363A1 WO2000027363A1 (en) | 2000-05-18 |
WO2000027363B1 true WO2000027363B1 (en) | 2000-07-13 |
WO2000027363A9 WO2000027363A9 (en) | 2000-11-30 |
Family
ID=22700162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/026799 WO2000027363A1 (en) | 1998-11-12 | 1999-11-12 | Aerosols comprising nanoparticle drugs |
Country Status (12)
Country | Link |
---|---|
US (4) | US7521068B2 (en) |
EP (2) | EP1128814B1 (en) |
JP (1) | JP4758548B2 (en) |
AT (2) | ATE493971T1 (en) |
AU (1) | AU1346900A (en) |
CA (1) | CA2350074C (en) |
CY (2) | CY1111344T1 (en) |
DE (1) | DE69943112D1 (en) |
DK (2) | DK2263652T3 (en) |
ES (2) | ES2387749T3 (en) |
PT (1) | PT2263652E (en) |
WO (1) | WO2000027363A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
US8955512B2 (en) | 2001-06-05 | 2015-02-17 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US8991387B2 (en) | 2003-05-21 | 2015-03-31 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
US9233072B2 (en) | 2008-10-12 | 2016-01-12 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US9308280B2 (en) | 2008-10-12 | 2016-04-12 | Massachusetts Institute Of Technology | Targeting of antigen presenting cells with immunonanotherapeutics |
US9333179B2 (en) | 2007-04-04 | 2016-05-10 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9474717B2 (en) | 2007-10-12 | 2016-10-25 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
Families Citing this family (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0810853B1 (en) * | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
UA72189C2 (en) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Aqueous suspensions of 9-hydroxy-risperidone fatty acid esters provided in submicron form |
US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
US6969529B2 (en) | 2000-09-21 | 2005-11-29 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
CN100341483C (en) * | 2000-02-28 | 2007-10-10 | 维克丘拉有限公司 | Improvements in or relating to delivery of oral drugs |
GB0009773D0 (en) * | 2000-04-19 | 2000-06-07 | Univ Cardiff | Particulate composition |
US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
DE10043509A1 (en) * | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Solid peptide preparations for inhalation and their manufacture |
US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
US7998507B2 (en) | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
DE10058772A1 (en) * | 2000-11-27 | 2002-06-06 | Falk Pharma Gmbh | Process for the preparation of readily soluble pharmaceutical formulations and corresponding formulations |
US20040052733A1 (en) * | 2000-11-30 | 2004-03-18 | Staniforth John Nicholas | Pharmaceutical compositions for inhalation |
EP3269360A1 (en) * | 2000-11-30 | 2018-01-17 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
AU2211502A (en) * | 2000-11-30 | 2002-06-11 | Vectura Ltd | Method of making particles for use in a pharmaceutical composition |
DE60140268D1 (en) * | 2000-11-30 | 2009-12-03 | Vectura Ltd | PARTICLES FOR USE IN A PHARMACEUTICAL COMPOSITION |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
GB0107106D0 (en) * | 2001-03-21 | 2001-05-09 | Boehringer Ingelheim Pharma | Powder inhaler formulations |
CZ301676B6 (en) * | 2001-03-30 | 2010-05-19 | Jagotec Ag | Pharmaceutical suspension aerosol formulation for inhalation and use of carboxylic acid salt |
DE60230609D1 (en) * | 2001-05-24 | 2009-02-12 | Alexza Pharmaceuticals Inc | ADMINISTRATION OF NON-TEROIDAL INFLAMMATION OF INHALATION OF ACTIVE SUBSTANCES |
WO2002094229A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of muscle relaxants through an inhalation route |
US7078016B2 (en) | 2001-11-21 | 2006-07-18 | Alexza Pharmaceuticals, Inc. | Delivery of caffeine through an inhalation route |
US6737042B2 (en) | 2001-05-24 | 2004-05-18 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
US20030095928A1 (en) * | 2001-09-19 | 2003-05-22 | Elan Pharma International Limited | Nanoparticulate insulin |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
IL160570A0 (en) | 2001-09-26 | 2004-07-25 | Baxter Int | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
WO2003043586A2 (en) * | 2001-11-20 | 2003-05-30 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
PL209212B1 (en) | 2002-03-01 | 2011-08-31 | Chiesi Farma Spa | Formoterol superfine formulation |
ATE343376T1 (en) * | 2002-03-20 | 2006-11-15 | Elan Pharma Int Ltd | NANOPARTICLE COMPOSITIONS OF ANGIOGENESIS INHIBITORS |
US20030185762A1 (en) * | 2002-03-22 | 2003-10-02 | Cowan Siu Man L. | Highly aqueous liquid carrier formulations |
GB0219815D0 (en) | 2002-08-24 | 2002-10-02 | Accentus Plc | Preparation of small crystals |
FI20020857A (en) * | 2002-05-07 | 2003-11-08 | Focus Inhalation Oy | Conversion of amorphous material to a corresponding crystalline material by spray drying and utilization of the crystalline spray-dried material in drug formulations |
MXPA04012720A (en) * | 2002-06-17 | 2007-03-23 | Epigenesis Pharmaceuticals Llc | Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compostions thereof. |
WO2004006959A1 (en) * | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
US20040045546A1 (en) * | 2002-09-05 | 2004-03-11 | Peirce Management, Llc | Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use |
US20040105778A1 (en) * | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
MXPA05004278A (en) | 2002-10-25 | 2005-10-05 | Foamix Ltd | Cosmetic and pharmaceutical foam. |
US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
JP4707937B2 (en) * | 2003-02-28 | 2011-06-22 | ホソカワミクロン株式会社 | Method for producing drug-containing composite particles and transpulmonary preparation |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
US7811606B2 (en) | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
JP2007501683A (en) * | 2003-05-22 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | Sterilization of nanoparticle active substance dispersions by gamma irradiation |
US20040242729A1 (en) * | 2003-05-30 | 2004-12-02 | 3M Innovative Properties Company | Stabilized particle dispersions containing surface-modified inorganic nanoparticles |
US7109247B2 (en) * | 2003-05-30 | 2006-09-19 | 3M Innovative Properties Company | Stabilized particle dispersions containing nanoparticles |
US7459146B2 (en) * | 2003-05-30 | 2008-12-02 | 3M Innovative Properties Company | Stabilized aerosol dispersions |
DE10325989A1 (en) * | 2003-06-07 | 2005-01-05 | Glatt Gmbh | Process for the preparation of and resulting micropellets and their use |
US20060251584A1 (en) * | 2003-06-11 | 2006-11-09 | Nara Machinery Co., Ltd. | Drug nano-particle, method and apparatus for preparing pharmaceutical preparation using the particle |
WO2004112799A1 (en) * | 2003-06-13 | 2004-12-29 | Chrysalis Technologies Incorporated | Methods and apparatus for producing nanoscale particles |
US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
EP1663164A2 (en) * | 2003-09-15 | 2006-06-07 | Vectura Limited | Methods for preparing pharmaceutical compositions |
US20060263350A1 (en) * | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
GB0323684D0 (en) | 2003-10-09 | 2003-11-12 | Jagotec Ag | Improvements in or relating to organic compounds |
WO2005077339A1 (en) * | 2004-02-10 | 2005-08-25 | E.I. Dupont De Nemours And Company | Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister |
WO2005084710A2 (en) * | 2004-03-02 | 2005-09-15 | Massachusetts Institute Of Technology | Nanocell drug delivery system |
US20070053845A1 (en) * | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
AU2005244128B2 (en) * | 2004-05-07 | 2009-06-25 | President And Fellows Of Harvard College | Pulmonary malarial vaccine |
US20060009435A1 (en) * | 2004-06-23 | 2006-01-12 | Joseph Kaspi | Synthesis and powder preparation of fluticasone propionate |
GB0418791D0 (en) * | 2004-08-23 | 2004-09-22 | Glaxo Group Ltd | Novel process |
WO2006026502A1 (en) | 2004-08-27 | 2006-03-09 | The Dow Chemical Company | Enhanced delivery of drug compositions to treat life threatening infections |
US20060073173A1 (en) * | 2004-10-04 | 2006-04-06 | Maria Banach | Large-scale manufacturing process for the production of pharmaceutical compositions |
RU2007119721A (en) | 2004-10-29 | 2008-12-10 | Президент Энд Феллоуз Оф Гарвард Колледж (Us) | PARTICLES FOR TREATMENT OF PULMONARY INFECTION |
US7910577B2 (en) * | 2004-11-16 | 2011-03-22 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
UA89513C2 (en) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Nanoparticulate raloxifene hydrochloride composition |
CA2590675A1 (en) * | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Nanoparticulate tacrolimus formulations |
US20060159767A1 (en) * | 2004-12-22 | 2006-07-20 | Elan Pharma International Limited | Nanoparticulate bicalutamide formulations |
CN101132770A (en) * | 2005-01-06 | 2008-02-27 | 伊兰制药国际有限公司 | Nanoparticulate candesartan formulations |
CA2597716A1 (en) * | 2005-02-15 | 2006-08-24 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
US20070065359A1 (en) * | 2005-03-14 | 2007-03-22 | Shiladitya Sengupta | Nanocells for diagnosis and treatment of diseases and disorders |
KR20070118258A (en) * | 2005-03-16 | 2007-12-14 | 엘란 파마 인터내셔널 리미티드 | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
MX2007011495A (en) * | 2005-03-17 | 2007-12-06 | Elan Pharma Int Ltd | Nanoparticulate biphosphonate compositions. |
EA200702049A1 (en) * | 2005-03-23 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | COMPOSITIONS OF CORTICOSTEROID NANOPARTICLES WITH ANTIGISTAMINS |
MX2007012778A (en) * | 2005-04-12 | 2008-01-11 | Elan Pharma Int Ltd | Nanoparticulate quinazoline derivative formulations. |
US20060246141A1 (en) * | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
US20090081297A1 (en) * | 2005-04-27 | 2009-03-26 | Cook Robert O | Use of surface tension reducing agents in aerosol formulations |
CA2612994A1 (en) | 2005-06-08 | 2006-12-08 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cefditoren |
US7947308B2 (en) * | 2005-07-20 | 2011-05-24 | Raimar Loebenberg | Effervescent powders for inhalation |
JP2007079857A (en) * | 2005-09-13 | 2007-03-29 | Canon Inc | Server apparatus, client apparatuses and those control methods, computer program, storage medium |
EP1933814A2 (en) | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
JP2009514902A (en) * | 2005-11-11 | 2009-04-09 | バイオラブ・サヌス・ファーマセウティカ・エルティーディーエー. | Solid pharmaceutical composition comprising aggregated nanoparticles and method for producing the same |
EP1968550A2 (en) * | 2005-12-16 | 2008-09-17 | University Of Kansas | Nanoclusters for delivery of therapeutics |
EP1798504A1 (en) * | 2005-12-19 | 2007-06-20 | Koninklijke Philips Electronics N.V. | Method of making dried particles |
US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
US20070202182A1 (en) * | 2006-02-26 | 2007-08-30 | Kane Kevin M | Preparing solid formulation of nanoparticles of pharmaceutical ingredient, including at least micron-sized particles |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
FI20060428L (en) * | 2006-05-03 | 2007-11-04 | Esko Kauppinen | Surface-modified aerosol particles, method and device for their production and powders and dispersions containing said particles |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
CA2653384C (en) | 2006-06-30 | 2017-03-14 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
US9044391B2 (en) | 2007-01-10 | 2015-06-02 | Board Of Regents, The University Of Texas System | Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery |
JP2008222567A (en) * | 2007-03-08 | 2008-09-25 | Iwate Univ | Method for producing fine particles |
WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
US8540969B2 (en) * | 2007-04-18 | 2013-09-24 | Particle Sciences, Inc. | Aerosol dispersions of particles with active pharmaceutical ingredients |
CN101702878B (en) * | 2007-05-11 | 2012-11-28 | 弗·哈夫曼-拉罗切有限公司 | Pharmaceutical compositions for poorly soluble drugs |
GB0712454D0 (en) * | 2007-06-27 | 2007-08-08 | Generics Uk Ltd | Pharmaceutical compositions |
WO2009020434A1 (en) * | 2007-08-07 | 2009-02-12 | Nanomaterials Technology Pte Ltd | A process for making micro-sized protein particles |
US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
CA2702094C (en) | 2007-10-10 | 2018-05-01 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
CA2702261A1 (en) * | 2007-10-12 | 2009-04-16 | Map Pharmaceuticals, Inc. | Inhalation drug delivery |
WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
WO2009073843A1 (en) * | 2007-12-06 | 2009-06-11 | Cytotech Labs, Llc | Inhalable compositions having enhanced bioavailability |
WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
US20090238867A1 (en) * | 2007-12-13 | 2009-09-24 | Scott Jenkins | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same |
EP2534957B1 (en) | 2007-12-14 | 2015-05-27 | AeroDesigns, Inc | Delivering aerosolizable products |
CA2712120A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
EP2095816A1 (en) * | 2008-02-29 | 2009-09-02 | Schlichthaar, Rainer, Dr. | Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety |
US20110182946A1 (en) * | 2008-03-17 | 2011-07-28 | Board Of Regents, The University Of Texas System | Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques |
WO2009158300A1 (en) * | 2008-06-26 | 2009-12-30 | 3M Innovative Properties Company | Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US20100119558A1 (en) * | 2008-11-10 | 2010-05-13 | Scandivir Ab | Ngna compositions and methods of use |
KR20100052262A (en) * | 2008-11-10 | 2010-05-19 | (주)아모레퍼시픽 | Process for preparing powder comprising nanoparticles of sparingly soluble drug, powder prepared by same process and pharmaceutical composition comprising same powder |
US9028878B2 (en) | 2009-02-03 | 2015-05-12 | Microbion Corporation | Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses |
JP5674684B2 (en) | 2009-02-03 | 2015-02-25 | マイクロビオン コーポレーション | Bismuth-thiol as a disinfectant for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
PT2400950T (en) | 2009-02-26 | 2019-08-29 | Glaxo Group Ltd | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
WO2010102065A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives |
CN102458380A (en) * | 2009-04-24 | 2012-05-16 | 先灵公司 | Agglomerate formulations including active pharmaceutical agents with targeted particle sizes |
KR20140077945A (en) | 2009-04-24 | 2014-06-24 | 아이슈티카 피티와이 리미티드 | A Novel formulation of indomethacin |
WO2010125470A2 (en) | 2009-04-28 | 2010-11-04 | Foamix Ltd. | Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
CA2763456C (en) | 2009-05-27 | 2017-10-24 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate active agent compositions |
AU2010254551B2 (en) | 2009-05-27 | 2016-10-20 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
US20100310660A1 (en) * | 2009-06-08 | 2010-12-09 | Taipei Medical University | Dry powder microparticles for pulmonary delivery |
CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
US20110033545A1 (en) * | 2009-08-06 | 2011-02-10 | Absize, Inc. | Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith |
US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
CA2776474C (en) | 2009-10-02 | 2021-01-12 | Foamix Ltd. | Topical tetracycline compositions |
GB0918149D0 (en) | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved medicinal aerosol formulation |
US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
GB201001070D0 (en) | 2010-01-22 | 2010-03-10 | St George's Hospital Medical School | Theraputic compounds and their use |
SG10201501872XA (en) | 2010-03-12 | 2015-05-28 | Berg Llc | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
EP2560624B1 (en) | 2010-04-23 | 2018-07-04 | KemPharm, Inc. | Therapeutic formulation for reduced drug side effects |
WO2011146583A2 (en) | 2010-05-19 | 2011-11-24 | Elan Pharma International Limited | Nanoparticulate cinacalcet formulations |
CA2798323A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
GB201011411D0 (en) | 2010-07-06 | 2010-08-18 | St Georges Hosp Medical School | Therapeutic compounds and their use |
US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
CA2812262A1 (en) * | 2010-09-22 | 2012-03-29 | Map Pharmaceuticals, Inc. | Aerosol composition for administering drugs |
JP2014504260A (en) * | 2010-10-15 | 2014-02-20 | グラクソ グループ リミテッド | Aggregated nanoparticulate drug formulation, its manufacture and use |
JOP20120023B1 (en) | 2011-02-04 | 2022-03-14 | Novartis Ag | Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases |
GB201102237D0 (en) * | 2011-02-09 | 2011-03-23 | Kuecept Ltd | Particle formulation |
CA2824639A1 (en) | 2011-02-17 | 2012-08-23 | Ashish Chatterji | A process for controlled crystallization of an active pharmaceutical ingredient from supercooled liquid state by hot melt extrusion |
US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
US8778383B2 (en) | 2011-06-07 | 2014-07-15 | Parion Sciences, Inc. | Methods of treatment |
US8945605B2 (en) * | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
JO3410B1 (en) * | 2011-06-07 | 2019-10-20 | Otsuka Pharma Co Ltd | Freeze-dried aripiprazole formulation |
PE20180414A1 (en) | 2011-06-17 | 2018-03-01 | Berg Llc | INHALABLE PHARMACEUTICAL COMPOSITIONS |
US20130028857A1 (en) | 2011-07-29 | 2013-01-31 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
EP2768481A4 (en) * | 2011-10-21 | 2015-07-08 | Subhash Desai | Compositions for reduction of side effects |
EP2601973A1 (en) | 2011-12-09 | 2013-06-12 | Laboratoires SMB SA | Dry powder formulation of azole derivative for inhalation |
CN104220123B (en) * | 2012-02-16 | 2017-08-25 | 卡普尼亚公司 | Gas distributor with diffusion nose |
BR112014025518B1 (en) * | 2012-04-13 | 2022-05-24 | Glaxosmithkline Intellectual Property Development Limited | Aggregate particles of umeclidinium, vilanterol and fluticasone, powder composition, inhaler, process for preparing aggregate particles, and, use of magnesium stearate in aggregate particles |
JP2016500620A (en) * | 2012-11-01 | 2016-01-14 | プレシジョン・バルブ・コーポレーション | Flowable aerosol valve |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
GB201307659D0 (en) * | 2013-04-26 | 2013-06-12 | Korea Coast Guard Commissioner | Preparation of drug particles by micronisation |
WO2014178891A1 (en) | 2013-04-30 | 2014-11-06 | Otitopic Inc. | Dry powder formulations and methods of use |
US20160317542A1 (en) | 2013-12-09 | 2016-11-03 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
WO2015127315A1 (en) | 2014-02-20 | 2015-08-27 | Otitopic Inc. | Dry powder formulations for inhalation |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
KR102551708B1 (en) | 2015-06-04 | 2023-07-06 | 크리티테크, 인크. | Collection device and method of use |
KR20230017354A (en) | 2016-04-04 | 2023-02-03 | 크리티테크, 인크. | Methods for Solid Tumor Treatment |
GB201609925D0 (en) * | 2016-06-07 | 2016-07-20 | Novabiotics Ltd | Formulation |
MX2020012139A (en) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Compositions and methods for treating rosacea and acne. |
JP2020523285A (en) | 2017-06-09 | 2020-08-06 | クリチテック,インコーポレイテッド | Treatment of epithelial cysts by intracystic injection of antitumor particles |
US10398646B2 (en) | 2017-06-14 | 2019-09-03 | Crititech, Inc. | Methods for treating lung disorders |
CN111278436A (en) | 2017-10-03 | 2020-06-12 | 克里蒂泰克公司 | Local delivery of anti-tumor particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer |
US11534397B2 (en) * | 2017-11-09 | 2022-12-27 | The Board Of Regents Of The University Of Oklahoma | Nanocrystal microparticles of poorly soluble drugs and methods of production and use thereof |
US11116220B2 (en) | 2017-12-22 | 2021-09-14 | Ecolab Usa Inc. | Antimicrobial compositions with enhanced efficacy |
CN108651937B (en) * | 2018-04-20 | 2021-12-24 | 大连工业大学 | Method for producing soup-stock seasoning powder based on ultrasonic spray freeze drying |
JP2021522308A (en) | 2018-05-04 | 2021-08-30 | トゥリーズ | TLR3 ligand that activates both epithelial and bone marrow cells |
EP3827260A4 (en) * | 2018-07-24 | 2022-05-04 | Board of Regents, The University of Texas System | Compositions of surface-modified therapeutically active particles by ultra-rapid freezing |
JP2021533193A (en) * | 2018-07-31 | 2021-12-02 | マイクロビオン コーポレーション | Bismuth thiol composition and usage |
CN112788950A (en) | 2018-07-31 | 2021-05-11 | 微生物公司 | Bismuth-thiol compositions and methods for treating wounds |
WO2022189861A1 (en) | 2021-03-08 | 2022-09-15 | Tollys | Carbohydrate conjugates of tlr3 ligands and uses thereof |
JP7401814B2 (en) * | 2021-12-14 | 2023-12-20 | ダイキン工業株式会社 | Spray equipment and air treatment equipment |
Family Cites Families (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3269798A (en) | 1962-01-26 | 1966-08-30 | Preston John Miles | Stabilized phosphoric acid |
NL289785A (en) * | 1962-11-29 | |||
US3692532A (en) | 1970-10-27 | 1972-09-19 | David R Shenkenberg | Milk-fruit juice beverage and process for preparing same |
SU628930A1 (en) | 1974-11-26 | 1978-10-25 | Московский научно-исследовательский институт туберкулеза | Device for introducing medicinal powders |
DE3013839A1 (en) | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | METHOD FOR PRODUCING AN ACTIVATED PHARMACEUTICAL COMPOSITION |
JPS5726615A (en) | 1980-07-23 | 1982-02-12 | Grelan Pharmaceut Co Ltd | Improving method for absorbability of slightly soluble drug |
US4389397A (en) | 1980-08-04 | 1983-06-21 | Merck & Co., Inc. | Solubilization of ivermectin in water |
JPS5846019A (en) | 1981-09-14 | 1983-03-17 | Kanebo Ltd | Nifedipine preparation with prolonged action |
JPS59101423A (en) | 1982-12-02 | 1984-06-12 | Takada Seiyaku Kk | Novel solid pharmaceutical preparation of nifedipine |
DE3318649A1 (en) | 1983-05-21 | 1984-11-22 | Bayer Ag, 5090 Leverkusen | TWO-PHASE FORMULATION |
US4917816A (en) | 1984-01-03 | 1990-04-17 | Abco Industries, Inc. | Stabilized peroxide compositions and process for producing same |
DE3421468A1 (en) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | LIPID NANOPELLETS AS A CARRIER SYSTEM FOR MEDICINAL PRODUCTS FOR PERORAL USE |
US4757059A (en) | 1984-08-14 | 1988-07-12 | International Copper Research Association | Method for treating convulsions and epilepsy with organic copper compounds |
US4663364A (en) | 1984-09-05 | 1987-05-05 | Kao Corporation | Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder |
FR2575678B1 (en) * | 1985-01-04 | 1988-06-03 | Saint Gobain Vitrage | PNEUMATIC POWDER EJECTOR |
US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
US4826821A (en) | 1985-06-26 | 1989-05-02 | The Regents Of The University Of California | Lung surfactant compositions |
IT1187751B (en) | 1985-10-15 | 1987-12-23 | Eurand Spa | PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED |
JPS62185013A (en) | 1986-02-08 | 1987-08-13 | Green Cross Corp:The | Easily absorbable pharmaceutical composition |
EP0262560A3 (en) | 1986-09-29 | 1989-07-05 | Ishihara Sangyo Kaisha, Ltd. | Benzoyl urea compound |
US4983605A (en) | 1986-10-23 | 1991-01-08 | Ishihara Sangyo Kaisha Ltd. | Pharmaceutical composition |
FR2608942B1 (en) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOCAPSULES |
FR2608988B1 (en) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES |
IT1217890B (en) | 1988-06-22 | 1990-03-30 | Chiesi Farma Spa | DOSED AEROSOL INHALATION DEVICE |
JP2661709B2 (en) | 1988-07-08 | 1997-10-08 | ダウ・ケミカル日本株式会社 | Production method of highly active pesticide wettable powder |
FR2635459B1 (en) | 1988-08-17 | 1992-06-19 | Cird | PROCESS FOR THE MANUFACTURE OF MICROSPHERES BY CROSSLINKING PROTEINS, MICROSPHERES THUS OBTAINED AND THEIR USES |
ES2052016T3 (en) | 1988-09-29 | 1994-07-01 | Shiseido Co Ltd | EMULSIFIED COMPOSITION. |
US5225183A (en) | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
JPH02196719A (en) | 1989-01-24 | 1990-08-03 | Green Cross Corp:The | Powdery drug composition |
JP2642486B2 (en) | 1989-08-04 | 1997-08-20 | 田辺製薬株式会社 | Ultrafine particle method for poorly soluble drugs |
GB2237510B (en) | 1989-11-04 | 1993-09-15 | Danbiosyst Uk | Small particle drug compositions for nasal administration |
JPH05963A (en) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | Polypeptide composition |
US5091187A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5091188A (en) | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
CA2053000C (en) | 1990-10-15 | 1995-08-29 | Michael J. Conder | Biosynthetic production of 6(r)-[2-(8(s)-hydroxy-2(s), 6(r)-dimethyl-1,2,6,7,8,8a(r)-hexahydronaphthyl)-ethyl]-4 (r)-hydroxy-3,4,5,6-tetrahydro-2h-pyran-2-one triol acid by enzymatic hydrolysis of lovastatin acid using an enzyme derived from__lonostachys compactiuscula |
GB9024365D0 (en) | 1990-11-09 | 1991-01-02 | Glaxo Group Ltd | Medicaments |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU642066B2 (en) | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
US5744123A (en) * | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
US5202110A (en) * | 1992-01-22 | 1993-04-13 | Virginia Commonwealth University | Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants |
JPH07112936A (en) | 1992-04-27 | 1995-05-02 | Philippe Perovich | Preparation of component for medical treatment, especially component based on aspirin |
US5300739A (en) | 1992-05-26 | 1994-04-05 | Otis Elevator Company | Cyclically varying an elevator car's assigned group in a system where each group has a separate lobby corridor |
US5719147A (en) * | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
US5785049A (en) * | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
FR2695563B1 (en) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticles carrying antigens and their use for the induction of humoral or cellular responses. |
ES2077547T3 (en) | 1992-11-17 | 2000-06-16 | Yoshitomi Pharmaceutical | SUSTAINED RELEASE MICROSPHERE CONTAINING AN ANTIPSYCHOTIC AND PRODUCTION PROCEDURE. |
FR2698560B1 (en) | 1992-11-30 | 1995-02-03 | Virbac Laboratoires | Stabilized powdery active ingredients, compositions containing them, process for obtaining them and their applications. |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5260478A (en) | 1992-12-08 | 1993-11-09 | Sterling Winthrop Inc. | Iodinated aroyloxy carboxamides |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5322679A (en) | 1992-12-16 | 1994-06-21 | Sterling Winthrop Inc. | Iodinated aroyloxy esters |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
BR9405798A (en) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Methods for in vivo release of biological material and useful compositions thereof |
CA2091152C (en) | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
US5264610A (en) | 1993-03-29 | 1993-11-23 | Sterling Winthrop Inc. | Iodinated aromatic propanedioates |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
DE4327063A1 (en) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenone particles with modified physicochemical properties |
US6177104B1 (en) | 1994-01-27 | 2001-01-23 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving dosage form |
US5711934A (en) | 1994-04-11 | 1998-01-27 | Abbott Laboratories | Process for the continuous milling of aerosol pharmaceutical formulations in aerosol propellants |
US5521168A (en) | 1994-10-13 | 1996-05-28 | Alcon Laboratories, Inc. | Estrogen metabolites for lowering intraocular pressure |
US5585108A (en) | 1994-12-30 | 1996-12-17 | Nanosystems L.L.C. | Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays |
US5466440A (en) | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
JPH10511957A (en) | 1995-01-05 | 1998-11-17 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン | Surface-modified nanoparticles and methods for their production and use |
JPH08259460A (en) | 1995-01-23 | 1996-10-08 | Takeda Chem Ind Ltd | Production of sustained release pharmaceutical preparation |
US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5518738A (en) | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5747001A (en) * | 1995-02-24 | 1998-05-05 | Nanosystems, L.L.C. | Aerosols containing beclomethazone nanoparticle dispersions |
EP0810853B1 (en) | 1995-02-24 | 2004-08-25 | Elan Pharma International Limited | Aerosols containing nanoparticle dispersions |
IL123636A (en) | 1995-12-27 | 2001-04-30 | Janssen Pharmaceutica Nv | Bioadhesive compositions, tablets comprising them and methods for preparing the tablets |
JPH09241178A (en) | 1996-03-07 | 1997-09-16 | Takeda Chem Ind Ltd | Production of sustained release pharmaceutical preparation of adenocorticotropic hormone derivative |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
EP0818450B1 (en) | 1996-07-08 | 2003-01-15 | Ciba SC Holding AG | Triazine derivatives as UV filter in sunscreen products |
RO120603B1 (en) | 1996-08-22 | 2006-05-30 | Research Triangle Pharmaceuticals Ltd. | Composition containing microparticles of water-insoluble substances and process for preparing the same |
GB2316316A (en) | 1996-08-23 | 1998-02-25 | Int Centre Genetic Eng & Bio | Sustained release of erythropoietin from microspheres |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
IN186315B (en) | 1996-12-12 | 2001-08-04 | Panacea Biotec Ltd | |
JPH10194996A (en) | 1996-12-25 | 1998-07-28 | Janssen Pharmaceut Nv | Acylated cyclodextrin-containing pharmaceutical composition |
WO1998029098A1 (en) | 1996-12-31 | 1998-07-09 | Inhale Therapeutic Systems, Inc. | Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
FR2758461A1 (en) | 1997-01-17 | 1998-07-24 | Pharma Pass | PHARMACEUTICAL COMPOSITION HAVING HIGH BIOAVAILABILITY AND PROCESS FOR PREPARING THE SAME |
WO1998035666A1 (en) | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
JP3950175B2 (en) | 1997-05-30 | 2007-07-25 | オスモティカ・コーポレイション | Multi-layer penetrating device |
ES2355186T3 (en) | 1997-09-05 | 2011-03-23 | Maruho K.K. | PREPARATIONS OF NANOCAPPSULES TO TREAT INTRAARTICULAR DISEASES. |
US20020002294A1 (en) | 1997-09-24 | 2002-01-03 | D' Amato Robert J. | Estrogenic compounds as antiangiogenic agents |
GB9726543D0 (en) | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Novel compositions |
US6086376A (en) * | 1998-01-30 | 2000-07-11 | Rtp Pharma Inc. | Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant |
ZA991922B (en) | 1998-03-11 | 1999-09-13 | Smithkline Beecham Corp | Novel compositions of eprosartan. |
US6177103B1 (en) | 1998-06-19 | 2001-01-23 | Rtp Pharma, Inc. | Processes to generate submicron particles of water-insoluble compounds |
US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
AU6283299A (en) | 1998-10-01 | 2000-04-17 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
ES2367352T3 (en) | 1999-04-28 | 2011-11-02 | Genetics Institute, Llc | TREATMENT OF MEASURING FIBROSIS THE ANTAGONISM OF IL-3 AND THE IL-3 RECEPTOR CHAINS. |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
GB9913536D0 (en) | 1999-06-10 | 1999-08-11 | Sterix Ltd | Use |
US6368620B2 (en) | 1999-06-11 | 2002-04-09 | Abbott Laboratories | Formulations comprising lipid-regulating agents |
US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
AR035642A1 (en) | 2000-05-26 | 2004-06-23 | Pharmacia Corp | USE OF A CELECOXIB COMPOSITION FOR QUICK PAIN RELIEF |
JP4295420B2 (en) | 2000-06-01 | 2009-07-15 | 株式会社リコー | Blank page printing method for printer control device |
MXPA02011891A (en) | 2000-06-02 | 2004-04-02 | Eidgenoess Tech Hochschule | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds. |
US6534088B2 (en) | 2001-02-22 | 2003-03-18 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
ATE343376T1 (en) | 2002-03-20 | 2006-11-15 | Elan Pharma Int Ltd | NANOPARTICLE COMPOSITIONS OF ANGIOGENESIS INHIBITORS |
EP1800666A1 (en) | 2002-03-20 | 2007-06-27 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
DE60325718D1 (en) | 2002-05-06 | 2009-02-26 | Elan Pharma Int Ltd | Nystatin NANOPARTICLE COMPOSITIONS |
EP1511468A1 (en) | 2002-06-10 | 2005-03-09 | Elan Pharma International Limited | Nanoparticulate sterol formulations and sterol combinations |
-
1998
- 1998-11-12 US US09/190,138 patent/US7521068B2/en not_active Expired - Lifetime
-
1999
- 1999-11-12 PT PT10179894T patent/PT2263652E/en unknown
- 1999-11-12 EP EP99956981A patent/EP1128814B1/en not_active Expired - Lifetime
- 1999-11-12 CA CA002350074A patent/CA2350074C/en not_active Expired - Fee Related
- 1999-11-12 AT AT99956981T patent/ATE493971T1/en active
- 1999-11-12 EP EP10179894A patent/EP2263652B1/en not_active Expired - Lifetime
- 1999-11-12 AT AT10179894T patent/ATE556702T1/en active
- 1999-11-12 DK DK10179894.0T patent/DK2263652T3/en active
- 1999-11-12 DE DE69943112T patent/DE69943112D1/en not_active Expired - Lifetime
- 1999-11-12 ES ES10179894T patent/ES2387749T3/en not_active Expired - Lifetime
- 1999-11-12 JP JP2000580594A patent/JP4758548B2/en not_active Expired - Fee Related
- 1999-11-12 WO PCT/US1999/026799 patent/WO2000027363A1/en active Application Filing
- 1999-11-12 AU AU13469/00A patent/AU1346900A/en not_active Abandoned
- 1999-11-12 ES ES99956981T patent/ES2359298T3/en not_active Expired - Lifetime
- 1999-11-12 DK DK99956981.7T patent/DK1128814T3/en active
-
2000
- 2000-06-19 US US09/597,738 patent/US6811767B1/en not_active Expired - Lifetime
-
2009
- 2009-01-26 US US12/320,431 patent/US8124057B2/en not_active Expired - Fee Related
-
2011
- 2011-03-21 CY CY20111100300T patent/CY1111344T1/en unknown
-
2012
- 2012-02-24 US US13/404,790 patent/US20120213829A1/en not_active Abandoned
- 2012-08-07 CY CY20121100709T patent/CY1112978T1/en unknown
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9211382B2 (en) | 2001-05-24 | 2015-12-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US9440034B2 (en) | 2001-05-24 | 2016-09-13 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
US9439907B2 (en) | 2001-06-05 | 2016-09-13 | Alexza Pharmaceutical, Inc. | Method of forming an aerosol for inhalation delivery |
US8955512B2 (en) | 2001-06-05 | 2015-02-17 | Alexza Pharmaceuticals, Inc. | Method of forming an aerosol for inhalation delivery |
US9308208B2 (en) | 2001-06-05 | 2016-04-12 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
US8991387B2 (en) | 2003-05-21 | 2015-03-31 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US9370629B2 (en) | 2003-05-21 | 2016-06-21 | Alexza Pharmaceuticals, Inc. | Self-contained heating unit and drug-supply unit employing same |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
US9333179B2 (en) | 2007-04-04 | 2016-05-10 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
US9474717B2 (en) | 2007-10-12 | 2016-10-25 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9526702B2 (en) | 2007-10-12 | 2016-12-27 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9539210B2 (en) | 2007-10-12 | 2017-01-10 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
US9439859B2 (en) | 2008-10-12 | 2016-09-13 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunoanotherapeutics |
US9308280B2 (en) | 2008-10-12 | 2016-04-12 | Massachusetts Institute Of Technology | Targeting of antigen presenting cells with immunonanotherapeutics |
US9233072B2 (en) | 2008-10-12 | 2016-01-12 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
Also Published As
Publication number | Publication date |
---|---|
CA2350074A1 (en) | 2000-05-18 |
ES2359298T3 (en) | 2011-05-20 |
ATE556702T1 (en) | 2012-05-15 |
US20120213829A1 (en) | 2012-08-23 |
CA2350074C (en) | 2004-03-23 |
DK2263652T3 (en) | 2012-08-20 |
DK1128814T3 (en) | 2011-03-07 |
WO2000027363A1 (en) | 2000-05-18 |
ATE493971T1 (en) | 2011-01-15 |
US20090181100A1 (en) | 2009-07-16 |
ES2387749T3 (en) | 2012-10-01 |
CY1111344T1 (en) | 2015-08-05 |
US8124057B2 (en) | 2012-02-28 |
US7521068B2 (en) | 2009-04-21 |
AU1346900A (en) | 2000-05-29 |
EP1128814B1 (en) | 2011-01-05 |
PT2263652E (en) | 2012-08-09 |
JP4758548B2 (en) | 2011-08-31 |
JP2002529396A (en) | 2002-09-10 |
US6811767B1 (en) | 2004-11-02 |
US20020102294A1 (en) | 2002-08-01 |
CY1112978T1 (en) | 2016-04-13 |
DE69943112D1 (en) | 2011-02-17 |
WO2000027363A9 (en) | 2000-11-30 |
EP2263652A1 (en) | 2010-12-22 |
EP2263652B1 (en) | 2012-05-09 |
EP1128814A1 (en) | 2001-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000027363B1 (en) | Aerosols comprising nanoparticle drugs | |
CA2218116C (en) | Pulmonary delivery of aerosolized medicaments | |
CA2304819C (en) | Perforated microparticles and methods of use | |
Smyth et al. | Carriers in drug powder delivery: implications for inhalation system design | |
US6660715B2 (en) | Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery | |
EP1343372A2 (en) | Pulmonary delivery of polyene antifungal agents | |
AU2002245181A1 (en) | Pulmonary delivery of polyene antifungal agents | |
EP1734938A1 (en) | Insulin highly respirable microparticles | |
US10993909B1 (en) | Method and composition for treating upper respiratory tract inflammatory and infectious diseases | |
JP2008511637A (en) | Enhanced supply of pharmaceutical compositions to treat fatal infections | |
Yang et al. | The effects of surface morphology on the aerosol performance of spray-dried particles within HFA 134a based metered dose formulations | |
EP0964675B1 (en) | Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it | |
US20060039985A1 (en) | Methotrexate compositions | |
US20110104362A1 (en) | Method of making a dry powder pharmaceutical composition | |
JP2002503703A (en) | Liquid crystalline form of cyclosporine | |
US20030007930A1 (en) | Novel methods and compositions for delivering macromolecules to or via the respiratory tract | |
Ely et al. | Development of inhalable nanoparticles | |
WO2009064469A1 (en) | Pulmonary delivery of a macrolide antibiotic | |
AU2369599A (en) | Pulmonary delivery of aerosolized medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 13469 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
B | Later publication of amended claims | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref document number: 2350074 Country of ref document: CA Ref country code: CA Ref document number: 2350074 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 580594 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999956981 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999956981 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |